Latest Intellectual Property News

Page 6 of 89
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
Foresta has secured acceptance of a Japanese patent for its rosin and terpene extraction technology while moving the Kawerau pine chemicals project through front-end design. But with $2.47 million in cash and estimated funding for 2.65 quarters, the next development stage will bring a financing question into sharper focus.
Victor Sage
Victor Sage
26 Oct 2026
Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
Ada Torres
26 Oct 2026
Dubber reported $1.3 million of positive operating cash flow in Q1 FY27, alongside $7.7 million in revenue and $16.2 million of total liquidity. The company is now shifting from cost reduction towards growth, with new AI products and the proposed Daisee acquisition next in line.
Sophie Babbage
Sophie Babbage
26 Oct 2026
Biome Australia has reported record pharmacy sell-through, further market-share gains and positive operating cash flow as it begins manufacturing Activated Probiotics domestically. The quarter also moved its China expansion and BMB18 clinical trial closer to key execution milestones.
Ada Torres
Ada Torres
26 Oct 2026
Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
Ada Torres
Ada Torres
26 Oct 2026
Zoono Group is seeking up to A$1.61 million from a non-renounceable rights issue after completing a separate A$250,000 placement, with its offer document warning of material uncertainty around going concern. The funds are intended to support shelf-life extension projects, intellectual property and working capital, but investors face dilution and an unresolved legal case.
Ada Torres
Ada Torres
23 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Jatcorp’s revenue rose 23% to $38.9 million in FY2026, but weaker margins, negative operating cash flow and a material going-concern uncertainty leave the nutritional products maker’s recovery unfinished. The company ended the year with $5.6 million in cash after a $4.2 million entitlement offer, while Neurio trademark litigation in China remains unresolved.
Victor Sage
Victor Sage
22 Oct 2026
Energy Technologies has outlined two signed commercial arrangements for its Cogenic laser display technology, including a SYNCH purchasing framework worth up to US$10 million and a 5% royalty licence with Amalgamated Vision. The opportunity is meaningful, but the SYNCH arrangement carries no minimum order commitment and still depends on product specifications, acceptance and purchase orders.
Sophie Babbage
Sophie Babbage
22 Oct 2026
Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.
Ada Torres
Ada Torres
22 Oct 2026
Laserbond delivered strong FY26 growth despite higher tungsten costs and soft mining demand, while securing a second Komatsu licensing agreement and a new international collaboration with Metal 7. The company is now positioning lower-tungsten products, new coatings and expanded capacity for a much larger market.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive